Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Moreau

Showing results (451-460 of 570) with videos related to

Pageof 57
Sort By:
Leukemia|January 15, 2010
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasoneH Avet-Loiseau, J Soulier, J-P Fermand, et al.
Leukemia|March 10, 2015
Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myelomaE Brissot, A Clavert, N Blin, et al.
Journal of Medicinal Chemistry|October 28, 1997
Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl groupF Anizon, L Belin, P Moreau, et al.
Bone Marrow Transplantation|November 24, 2015
Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseasesA Le Bourgeois, F Malard, P Chevallier, et al.
Genes and Immunity|December 20, 2013
Worldwide genetic variation at the 3' untranslated region of the HLA-G gene: balancing selection influencing genetic diversityA Sabbagh, P Luisi, E C Castelli, et al.
Haematologica|May 3, 2008
Surgical treatment of a foscavir-resistant atypical Cytomegalovirus pneumonia in an allogeneic stem cell transplant recipientC Bressollette-Bodin, A Claver, D Boutolleau, et al.
The Journal of Biological Chemistry|April 15, 1988
Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activityD H Coy, P Heinz-Erian, N Y Jiang, et al.
Annals of Hematology|March 17, 2010
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myelomaA Palumbo, F Davies, M Kropff, et al.
Tissue Antigens|March 28, 2012
Identification of two new HLA-G alleles, G*01:01:03:03 and G*01:01:21, in Brazilian individualsE C Castelli, R S de Albuquerque, L C Veiga-Castelli, et al.
Blood Cancer Journal|February 25, 2014
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myelomaD S Siegel, P Richardson, M Dimopoulos, et al.
Pageof 57

Showing results (451-460 of 570) with videos related to

Sort By:
Pageof 57
Leukemia|January 15, 2010
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasoneH Avet-Loiseau, J Soulier, J-P Fermand, et al.
Leukemia|March 10, 2015
Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myelomaE Brissot, A Clavert, N Blin, et al.
Journal of Medicinal Chemistry|October 28, 1997
Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl groupF Anizon, L Belin, P Moreau, et al.
Bone Marrow Transplantation|November 24, 2015
Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseasesA Le Bourgeois, F Malard, P Chevallier, et al.
Genes and Immunity|December 20, 2013
Worldwide genetic variation at the 3' untranslated region of the HLA-G gene: balancing selection influencing genetic diversityA Sabbagh, P Luisi, E C Castelli, et al.
Haematologica|May 3, 2008
Surgical treatment of a foscavir-resistant atypical Cytomegalovirus pneumonia in an allogeneic stem cell transplant recipientC Bressollette-Bodin, A Claver, D Boutolleau, et al.
The Journal of Biological Chemistry|April 15, 1988
Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activityD H Coy, P Heinz-Erian, N Y Jiang, et al.
Annals of Hematology|March 17, 2010
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myelomaA Palumbo, F Davies, M Kropff, et al.
Tissue Antigens|March 28, 2012
Identification of two new HLA-G alleles, G*01:01:03:03 and G*01:01:21, in Brazilian individualsE C Castelli, R S de Albuquerque, L C Veiga-Castelli, et al.
Blood Cancer Journal|February 25, 2014
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myelomaD S Siegel, P Richardson, M Dimopoulos, et al.
Pageof 57